Skip to Content
Merck
All Photos(1)

Documents

300116S

Avanti

Control (5mL vial)

Avanti Research™ - A Croda Brand

Synonym(s):

Control (Pegylated Liposomal Vehicle), frozen liposomal suspension (buffer - 10% w/w sucrose, 10 mM histidine ~pH 6.5)

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

UNSPSC Code:
12352211
NACRES:
NA.25

Assay

>99% (HPLC/MS)

form

solution

packaging

pkg of 1 × 5 mL (300116S-1EA)

manufacturer/tradename

Avanti Research™ - A Croda Brand

application(s)

vaccine development

shipped in

dry ice

storage temp.

−20°C

General description

Formulation: A Pegylated, long-circulating liposomal formulation with an ammonium sulfate core. Liposomes are stored frozen for a longer shelf life.

Application

Control (5mL vial) has been used as a control for doxorubicin Hcl product (Dox2) to study its characteristics by asymmetrical-flow field flow fractionation (MD-AF4). It may be used as a vehicle control liposome for liposomal encapsulated doxorubicin (Dox-NP).

Packaging

10 mL clear serum vial (300116S-1EA)

Legal Information

Avanti Research is a trademark of Avanti Polar Lipids, LLC

Storage Class Code

12 - Non Combustible Liquids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Physical characterization of liposomal drug formulations using multi-detector asymmetrical-flow field flow fractionation
Parot J, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society (2020)
J Parot et al.
Journal of controlled release : official journal of the Controlled Release Society, 320, 495-510 (2020-02-01)
Liposomal formulations for the treatment of cancer and other diseases are the most common form of nanotechnology enabled pharmaceuticals (NEPs) submitted for market approval and in clinical application today. The accurate characterization of their physical-chemical properties is a key requirement;

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service